DiaMedica Therapeutics' Q4 earnings report showed a performance in line with expectations, indicating stability in its financial performance. Historically, a positive earnings surprise in the previous quarter led to a significant stock price increase. However, this quarter's exact match with estimates, combined with unchanged revenue, suggests a neutral short-term impact on the stock price. The historical context of the previous quarter's performance provides a basis for potential investor optimism, but the lack of growth in revenue and the exact match to earnings estimates this quarter tempers expectations for immediate stock price movement.